116,216 research outputs found
Gastronomía Garífuna: Preparación y Consumo del Bami o Ereba
No full textThis article contains part of the results of a gastronomical investigation about the bami or ereba, a typical dish whose elaboration is part of the garifuna culinary tradition and identity. Through interviews with cultural carriers and the discussion of the topic in a focal group, the author collected information about the ancestral instruments and the ones presently used in its elaboration; the ingredients, form and time for its preparation and preservation; the way of transmitting the recipe; causes of the decrease of its preparation; forms of promoting its consumption and some proposals for its revitalization. DOI: http://dx.doi.org/10.5377/wani.v67i0.1884Este artículo contiene parte de los resultados de una investigación gastronómica sobre el bami o ereba, un platillo típico cuya elaboración forma parte de la tradición culinaria e identidad garífuna. Mediante entrevistas con portadores culturales y la discusión sobre el tema en un grupo focal, la autora recogió información sobre los instrumentos ancestrales y los utilizados actualmente en su elaboración; los ingredientes, forma y tiempo empleado para la preparación y vencimiento; la manera de transmitir su elaboración; causas del decrecimiento en la elaboración del bami; formas de promover su consumo, y algunas propuestas para su revitalización.Garifuna balna plun kakaswa satni kidika: ampat Bami awaskat Ereba atwa kidi yamwi didiwa kidika. Akat ulwi yakna stadi munwi laihwi tatalna dai kidi garifuna balna plun kakaswa satni kidika dawak Bami awaskat Ereba yulni kidika, adika kuduh sara puyuni plun ni satni as ki, adika plun ni ridi yamnin lani kidika garifuna balna sara puyuni kaupak plun ni aihwa as kapat duduwi,.Adika muihni balna ampat yalalahwa kidi yulni amanglalawa muihni balna dawak stadi munwi laihwi tatalyang muihni balna aslah kalalahna balna karak bik yulbauwi tatalna usnit yakat adika ulwi yakna daniwan kidi yul mahni ulwi duna dai, sara puyuni kau adika plun ni ampat yus mumunwa dai kidi dawak waradi ampat adi plun ni kidi ridi yayamwa kidi yulni, baisa auhni yamnin atwi ais ais ahawa kidi, dawak taim ampus diswa kidi adika plun ni yamwi, kaput bik ais puyuni kat adika plun ni daukalwa kidika, kaut bik ampat muih balna kau yamwi niningna kanin kidika, dawak bami awaskat ereba plun ni kidi ais yulni tanit kau sip barakwi kiwas kidi, muih balna kau baisa kalawa kat kakaswa atnin lani, dawak baisa tanit kau barakwi kiunin sinsni lani balna ulwi yaknin.DOI: http://dx.doi.org/10.5377/wani.v67i0.188
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial
No full textOver the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2–8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial.
No full textThis is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal, following peer review. The version of record: Anthony Mathur, Francisco Fernández-Avilés, Jozef Bartunek, Ann Belmans, Filippo Crea, Sheik Dowlut, Manuel Galiñanes, Marie-Claire Good, Juha Hartikainen, Christine Hauskeller, Stefan Janssens, Petr Kala, Jens Kastrup, John Martin, Philippe Menasché, Ricardo Sanz-Ruiz, Seppo Ylä-Herttuala, Andreas Zeiher, BAMI Group, The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial, European Heart Journal, ehaa651, https://doi.org/10.1093/eurheartj/ehaa651 is available online at: https://doi.org/10.1093/eurheartj/ehaa651AIMS : Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. METHODS AND RESULTS : Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. Unexpectedly low recruitment means the trial no longer qualifies as a hypothesis-testing trial, but is instead an observational study with no definitive conclusions possible from statistical analysis. In total, 375 patients were recruited: 185 patients were randomized to the treatment arm (intracoronary infusion of BM-MNCs 2-8 days after PPCI) and 190 patients to the control arm (optimal medical therapy). All-cause mortality at 2 years was 3.26% [6 deaths; 95% confidence interval (CI): 1.48-7.12%] in the BM-MNC group and 3.82% (7 deaths; 95% CI: 1.84-7.84%) in the control group. Five patients (2.7%, 95% CI: 1.0-5.9%) in the BM-MNC group and 15 patients (8.1%, CI : 4.7-12.5%) in the control group were hospitalized for heart failure during 2 years of follow-up. Neither adverse events nor serious adverse events differed between the two groups. There were no patients hospitalized for stroke in the control group and 4 (2.2%) patients hospitalized for stroke in the BM-MNC group. CONCLUSIONS : Although BAMI is the largest trial of autologous cell-based therapy in the treatment of AMI, unexpectedly low recruitment and event rates preclude any meaningful group comparisons and interpretation of the observed results
Final report and recommendations of the Health Information Exchange Use Case Design Group : report prepared for : the Connecticut Health IT Advisory Council / prepared by Michael Matthews (chief strategy officer), Carol Robinson (chief executive officer)
No full text1 online resource (19 pages)"Contributors: Stacy Beck, Pat Checko, DrPH, Kathy DeMatteo, Gerard Muro, MD, Mark Raymond, Jake Star, Lisa Stump, MS, RPh."; "October 31, 2017."; Includes bibliographical reference
Beta-blocker effect on ST-segment:a prespecified analysis of the EARLY-BAMI randomised trial
No full textObjective The effect of early intravenous (IV) beta-blockers (BBs) administration in patients undergoing primary percutaneous coronary intervention (pPCI) on ST-segment deviation is unknown. We undertook a prespecified secondary analysis of the Early Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction (EARLY-BAMI) trial to investigate the effect of early IV BB on ST-segment deviation.Methods The EARLY-BAMI trial randomised patients with ST-elevation myocardial infarction (STEMI) to IV metoprolol (2x5 mg bolus) or matched placebo before pPCI. The prespecified outcome, evaluated by an independent core laboratory blinded to study treatment, was the residual ST-segment deviation 1 hour after pPCI (ie, the percentage of patients with >3 mm cumulative ST deviation at 1 hour after pPCI).Results An ECG for the evaluation of residual ST-segment deviation 1 hour after pPCI was available in 442 out of 683 randomised patients. The BB group had a lower heart rate after pPCI compared with placebo (71.2 +/- 13.2 vs 74.3 +/- 13.6, p=0.016); however, no differences were noted in the percentages of patients with >3 mm cumulative ST deviation at 1 hour after pPCI (58.6% vs 54.1%, p=0.38, in BB vs placebo, respectively) neither a significant difference was found for the percentages of patients in each of the four prespecified groups (normalised ST-segment; 1-3 mm; 4-6 mm;>6 mm residual ST-deviation).Conclusions In patients with STEMI, who were being transported for primary PCI, early IV BB administration did not significantly affect ST-segment deviation after pPCI compared with placebo. The neutral result of early IV BB administration on an early marker of pharmacological effect is consistent with the absence of subsequent improvement of clinical outcomes.</p
The UN-SUSTAINABLE Match in HCV Recipients. Evidences from the Italian D-MELD Study on Balancing Donor-Recipient Risk Factors
No full textThe UN-SUSTAINABLE Match in HCV Recipients. Evidences from the Italian D-MELD Study on Balancing Donor-Recipient Risk Factor
Unlocking the mysteries of the past: Searching for clues in medieval manuscripts
No full textThis project looks at the reproduction of one mid-12th-century Roman text by analyzing sixteen versions of it that still exist, copied from c. 1160 through c. 1325. The author was Nicolaus Maniacutius, a cleric at St. John Lateran Basilica in Rome. That original copy is lost, but versions quickly appeared in monasteries and cathedrals in Italy, Germany, France, and England. Somehow, through networks of communication and travel, reproductions were made and collected by prominent monasteries and churches, and by the Guildhall, a secular institution in the City of London
Pulse oximetry adoption and oxygen orders at paediatric admission over 7 years in Kenya: a multihospital retrospective cohort study
No full textObjectives To characterise adoption and explore specific clinical and patient factors that might influence pulse oximetry and oxygen use in low-income and middle-income countries (LMICs) over time; to highlight useful considerations for entities working on programmes to improve access to pulse oximetry and oxygen.
Design A multihospital retrospective cohort study.
Settings All admissions (n=132 737) to paediatric wards of 18 purposely selected public hospitals in Kenya that joined a Clinical Information Network (CIN) between March 2014 and December 2020.
Outcomes Pulse oximetry use and oxygen prescription on admission; we performed growth-curve modelling to investigate the association of patient factors with study outcomes over time while adjusting for hospital factors.
Results Overall, pulse oximetry was used in 48.8% (64 722/132 737) of all admission cases. Use rose on average with each month of participation in the CIN (OR: 1.11, 95% CI 1.05 to 1.18) but patterns of adoption were highly variable across hospitals suggesting important factors at hospital level influence use of pulse oximetry. Of those with pulse oximetry measurement, 7% (4510/64 722) had hypoxaemia (SpO2 <90%). Across the same period, 8.6% (11 428/132 737) had oxygen prescribed but in 87%, pulse oximetry was either not done or the hypoxaemia threshold (SpO2 <90%) was not met. Lower chest-wall indrawing and other respiratory symptoms were associated with pulse oximetry use at admission and were also associated with oxygen prescription in the absence of pulse oximetry or hypoxaemia.
Conclusion The adoption of pulse oximetry recommended in international guidelines for assessing children with severe illness has been slow and erratic, reflecting system and organisational weaknesses. Most oxygen orders at admission seem driven by clinical and situational factors other than the presence of hypoxaemia. Programmes aiming to implement pulse oximetry and oxygen systems will likely need a long-term vision to promote adoption, guideline development and adherence and continuously examine impact
Beta-blocker effect on ST-segment: a prespecified analysis of the EARLY-BAMI randomised trial
No full textObjective: The effect of early intravenous (IV) beta-blockers (BBs) administration in patients undergoing primary percutaneous coronary intervention (pPCI) on ST-segment deviation is unknown. We undertook a prespecified secondary analysis of the Early Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction (EARLY-BAMI) trial to investigate the effect of early IV BB on ST-segment deviation. Methods: The EARLY-BAMI trial randomised patients with ST-elevation myocardial infarction (STEMI) to IV metoprolol (2×5 mg bolus) or matched placebo before pPCI. The prespecified outcome, evaluated by an independent core laboratory blinded to study treatment, was the residual ST-segment deviation 1 hour after pPCI (ie, the percentage of patients with >3 mm cumulative ST deviation at 1 hour after pPCI). Results: An ECG for the evaluation of residual ST-segment deviation 1 hour after pPCI was available in 442 out of 683 randomised patients. The BB group had a lower heart rate after pPCI compared with placebo (71.2±13.2 vs 74.3±13.6, p=0.016); however, no differences were noted in the percentages of patients with >3 mm cumulative ST deviation at 1 hour after pPCI (58.6% vs 54.1%, p=0.38, in BB vs placebo, respectively) neither a significant difference was found for the percentages of patients in each of the four prespecified groups (normalised ST-segment; 1-3 mm; 4-6 mm;>6 mm residual ST-deviation). Conclusions: In patients with STEMI, who were being transported for primary PCI, early IV BB administration did not significantly affect ST-segment deviation after pPCI compared with placebo. The neutral result of early IV BB administration on an early marker of pharmacological effect is consistent with the absence of subsequent improvement of clinical outcomes.Dutch Heart Foundation (Utrecht, the Netherlands, no. 2010B125) and an unrestricted grant by Medtronic Inc. (Heerlen, the Netherlands).No data JCR 20201.050 SJR (2020) Q1, 82/349 Cardiology and Cardiovascular MedicineNo data IDR 2020UE
Author insights 2015 survey
No full textThe annual Author Insights Survey, run by Nature Publishing Group (NPG) and sister company Palgrave Macmillan forms part of a wider research programme which aims to understand general author attitudes and behaviours around publishing, to track any changes over time.
The survey is conducted for internal purposes each year to provide longitudinal data and track changes in attitudes and behaviours. This year’s survey included questions on topics as diverse as factors that contribute to a journal’s reputation, the value of services offered by publishers and authors’ ideal audiences for their research. Demographic questions were also included in the survey to enable analysis by fields such as region and discipline
- …
